Insilico and TaiGen Achieve Milestone in Collaboration: Out-Licensed CKD Anemia Candidate ISM4808 Completes first human enrollment and dosing in Phase I clinical trial

2026-03-06 - 11:36

CAMBRIDGE, Mass., March 5, 2026 /PRNewswire/ — Insilico Medicine (Insilico Medicine, HKEX: 03696), a clinical-stage biotechnology company powered by generative artificial intelligence (AI), announced that ISM4808, an AI-driven PHD inhibitor for chronic kidney disease (CKD)-related anemia previously out-licensed to TaiGen Biotechnology (TaiGen*-KY, 4157), has achieved its first milestone. Recently, TaiGen has successfully completed the enrollment